

***Fiscal Year 2017 Alcohol and Substance Abuse Disorders Research Program
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Consortium Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • <u>Program Announcement</u> • <u>General Application Instructions</u> <p>Grants.gov Funding Opportunity Number: <u>W81XWH-17-ASADRP-CA</u></p>	<p>Independent intramural (DoD) and extramural investigators at all academic levels (or equivalent) are eligible to submit applications</p>	<ul style="list-style-type: none"> • The program's approach is to organize multidisciplinary, team-based translational research efforts to: • Identify promising compounds; • Conduct proof-of-principle basic research to determine which compounds are most appropriate for human research trials; • Conduct human proof-of-concept trials with promising compounds. This approach should accelerate the translation of contemporary basic science knowledge into enhanced clinical pharmacological treatment protocols for ASUD, including a regulatory strategy for U.S. Food and Drug Administration (FDA) compliance. 	<ul style="list-style-type: none"> • The maximum period of performance is 5 years. • The ASADRP Consortium will be funded initially with allocations from the FY17 ASADRP Congressional appropriation (\$3.532M). • The maximum allowable total costs (direct and indirect) for the entire period of performance are \$10.596M (base year plus 2 option years). • Two additional options, to be included in the application, may be funded from allocations from the FY18 & FY19 Congressional appropriation (up to \$3.532M each year) subject to Government Steering Committee (GSC) review, approval of the Grants Officer, and receipt of future congressional appropriations. 	<p>Pre-Application (Letter of Intent): September 13, 2017 5:00 p.m. Eastern time (ET)</p> <p>Application: September 27, 2017 11:59 p.m. ET</p>